The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Olyushina E.M.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

Kuznetsova O.A.

Kafedra akusherstva i ginekologii Volgogradskogo gosudarstvennogo meditsinskogo universiteta

Telezhnikova I.M.

A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Department, Moscow, Russia

Vinogradov I.I.

Department of General Surgery, Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation, Ryazan, Russia

Moskvina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Immunohistochemical study of the MSI phenotype of urothelial bladder cancer

Authors:

Zavalishina L.É., Andreeva Yu.Yu., Olyushina E.M., Frank G.A., Kuznetsova O.A., Telezhnikova I.M., Vinogradov I.I., Moskvina L.V.

More about the authors

Read: 4357 times


To cite this article:

Zavalishina LÉ, Andreeva YuYu, Olyushina EM, et al. . Immunohistochemical study of the MSI phenotype of urothelial bladder cancer. Russian Journal of Archive of Pathology. 2020;82(1):5‑14. (In Russ.)
https://doi.org/10.17116/patol2020820115

References:

  1. Meléndez B, Campenhout Van C, Rorive S, Remmelink M, Salmon I, D’Haene N. Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res. 2018;7(6):661-667. https://doi.org/10.21037/tlcr.2018.08.02
  2. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333-339. https://doi.org/10.1038/nature12634
  3. Nemtsova MV, Mikhailenko DS, Kekeeva TV, Kuznetsova OA, Bashkatov SV, Kurynin RV, Popov AM, Popova OP, Shegai PV, Andreeva YuYu, Alekseev BYa, Enikeev ME, Alyaev YuG, Karyakin OB, Rusakov IG, Frank GA, Zaletaev DV. Molecular genetic markers in oncourology. Molekulyarnaya meditsina. 2007;3:43-54. (In Russ.)
  4. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-1920. https://doi.org/10.1016/S0140-6736(16)00561-4
  5. Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44-56. https://doi.org/10.1093/annonc/mdy495
  6. Chang L, Chang M, Chang HM, Chang F. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol. 2018;26(2):e15-e21. https://doi.org/10.1097/PAI.0000000000000575
  7. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43-51. https://doi.org/10.1158/2159-8290.CD-14-0863
  8. McCarthy AJ, Capo‐Chichi J, Spence T, Grenier S, Stockley T, Kamel‐Reid S, Serra S, Sabatini P, Chetty R. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J Pathol Clin Res. 2019;5:115-129. https://doi.org/10.1002/cjp2.120
  9. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813-820. https://doi.org/10.1158/1078-0432.CCR-15-1678
  10. Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer. 2003;105(4):484-490. https://doi.org/10.1002/ijc.11109
  11. van der Post RS, Kiemeney LA, Ligtenberg MJ, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, Schaap L, Kets CM, van Krieken JH, Hoogerbrugge N. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet. 2010;47(7):464-470. https://doi.org/10.1136/jmg.2010.076992
  12. Saetta AA, Korkolopoulou P, Karlou M, Levidou G, Goudopoulou A, Thymara I, Stamatelli A, Tzivras M, Michalopoulos NV, Thomas-Tsagli E, Patsouris E. TGF-betaRII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 alterations are not associated with microsatellite instability or p53 mutations in invasive urothelial carcinoma of the urinary bladder. Pathology. 2007;39(4):425-432. https://doi.org/10.1080/00313020701444457
  13. Kassem HS, Varley JM, Hamam SM, Margison GP. Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer. Br J Cancer. 2001;84(3):321-328. https://doi.org/10.1054/bjoc.2000.1595

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.